<DOC>
	<DOCNO>NCT02727205</DOCNO>
	<brief_summary>STUDY TITLE : A Multiple Site Study Evaluate Irritation Sensitization Potential Repeat Applications Rotigotine Transdermal System , 1 mg/24 hr Versus Neupro ( Rotigotine Transdermal System ) , 1 mg/24 hr Healthy Volunteers TEST DRUG / INVESTIGATIONAL PRODUCT : Rotigotine Transdermal System , 1 mg/24 hr INDICATION STUDIED : Bioequivalence - Irritation Sensitization STUDY DESIGN : - Multiple-site , randomize , multiple-application , evaluator-blinded , control study - One-half ( ½ ) test patch one-half ( ½ ) reference patch apply daily site product 21 day period follow rest phase challenge phase</brief_summary>
	<brief_title>Irritation Sensitization Potential Repeat Applications Rotigotine Patch</brief_title>
	<detailed_description />
	<mesh_term>N 0437</mesh_term>
	<criteria>Healthy male nonpregnant female volunteer . All subject healthy , nonsmoking male female ( nonpregnant ) volunteer age 18 65 , demonstrate generally healthy screen medical medication history , physical examination , vital sign , 12lead electrocardiogram ( ECG ) , FSH level ( applicable ) . 1 . Reported receiving investigational drug within 30 day prior Day 1 patch application . 2 . Reported clinically significant illness 28 day prior Day 1 patch application ( determined Investigator [ ] ) . 3 . Reported history allergic response ( ) rotigotine relate drug . 4 . Reported history sulfite sensitivity . 5 . Demonstrated clinically relevant finding , determine clinical Investigator ( ) , screen ECG , second thirddegree atrioventricular block complete bundle branch block , arrhythmia . 6 . Reported history asthma , orthostatic hypotension , dizziness , syncope , dyskinesia . At discretion Principal Investigator , subject history asthma mild asthma require regular treatment could include . 7 . Systolic blood pressure &lt; 100 &gt; 145 mmHg diastolic blood pressure &lt; 60 &gt; 95 mmHg screening measure supine position 5 minute rest ; heart rate &lt; 50 &gt; 100 screening . 8 . Reported history narrow angle glaucoma . 9 . Reported use monoamine oxidase ( MAO ) inhibitor , reserpine , methyldopa , antipsychotic , neuroleptic , benzodiazepine , antidepressant , clozapine , olanzapine , quetiapine , metoclopramide , risperidone within 3 month enrollment . 10 . Reported history somnolence and/or fall asleep without warn . 11 . Reported history significant dermatologic disease condition atopy , psoriasis . 12 . Reported history medical condition know alter skin appearance physiologic response ( eg diabetes , porphyria ) . 13 . Reported history significant dermatologic cancer ( eg melanoma , squamous cell carcinoma ) . Basal cell carcinomas superficial involve investigative site acceptable . 14 . Reported history condition would significantly influence immune response ( e.g . primary acquire immunodeficiency HIV positive AIDS , generalize drug reaction , neoplasms lymphoma leukemia , moderate severe rheumatoid arthritis active systemic lupus erythematosus ) . 15 . Demonstrated obvious difference skin color amongst application site , presence skin condition , excessive hair ( subject agree hair clip short [ shave ] prior patch application eligible ) , scar tissue , recent sunburn , tattoo , open sore , body piercing , brand intend site application would interfere placement study article , skin assessment reaction drug . 16 . Reported use immunosuppressive drug , include systemic topical corticosteroid retinoids within 28 day prior Day 1 patch application . 17 . Reported use medication treatment would significantly influence exaggerate response patch would alter inflammatory immune response patch within 21 day prior Day 1 patch application ( e.g . cyclosporine , tacrolimus , systemic topical corticosteroid , cytotoxic drug , immune globulin , Bacillus CalmetteGuerin [ BCG ] , monoclonal antibody , radiation therapy ) . 18 . Reported use antiinflammatory medication , include ibuprofen Celebrex , within 72 hour Day 1 patch application , exception steroid nose drop and/or eye drop . 19 . Reported use antihistamine topical drug patch site within 72 hour Day 1 patch application . 20 . Reported history anaphylactic reaction drug . At discretion Investigator , subject seasonal allergic rhinitis sensitivity environmental allergen could include . 21 . Reported history sensitivity allergy adhesive bandage , tape , transdermal system . 22 . Reported significant history allergy soap , lotion , emollient , ointment , cream , cosmetic , adhesive , latex . 23 . Reported history drug alcohol addiction abuse within past year . 24 . Was pregnant , lactating , breastfeeding , intend become pregnant course study ( female ) . 25 . Demonstrated positive pregnancy screen ( female ) . Subjects positive result screen exclude study . Subjects positive result study withdrawn . 26 . Reported smoke use tobacco product currently use nicotine product ( patch , gum , etc. ) . Ninety ( 90 ) day abstinence require . 27 . Reported plan undergo magnetic resonance image cardioversion procedure study period .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>March 2016</verification_date>
</DOC>